You are here: Home » PTI Stories » National » News
Business Standard

No shortage of APIs and formulations in the country: Govt

Health Medical Pharma

Press Trust of India  |  New Delhi 

The National Pharmaceutical Pricing Authority (NPPA) has been assured by pharma industry body IDMA that there is no shortage of active pharmaceutical ingredients and formulations in the country due to coronavirus outbreak, Rajya Sabha was informed on Friday.

"NPPA has informed that they have not received any reference regarding shortage of active pharmaceutical ingredients. The Indian Drug Manufacturers Association (IDMA) has assured that its members have enough stocks of APIs and formulations," Minister for Chemicals & Fertilizers DV Sadananda Gowda said in a reply.

NPPA has also informed that it has not received any reference from pharma associations regarding steep increase in price of medicines due to outbreak of COVID-19 (coronavirus) in China, he added.

"NPPA is monitoring the situation regularly to ensure that ceiling prices of essential medicines are not breached," Gowda said.

Moreover, the Department of Pharmaceuticals has constituted a committee under the chairmanship of Eshwara Reddy, Joint Drugs Controller, Central Drugs Standard Control Organization to address the issue of drug security in the country in the context of novel coronavirus outbreak in China, he added.

"Based on the recommendations of the committee, the department has issued necessary instructions to NPPA and Drugs Controller General of India (DCGI) to ensure adequate supply of APIs and formulations at affordable prices in the market and to prevent black-marketing, illegal hoarding, creating artificial shortages in the country," Gowda said.

The policies formulated by the government from time to time are designed to minimize country's dependence on imports and to give fillip to indigenous manufacturing, he added.

"In this direction, the Department of Pharmaceuticals has formulated a scheme namely 'Assistance to Bulk Drug Industry for Common Facility Centre' for providing assistance to bulk drug industry for common facility centre in any upcoming bulk drug park promoted by state governments/state corporations," Gowda said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, March 13 2020. 20:10 IST